Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms

Abstract

In this review, we highlight a number of the more important changes in the new revision as compared with the previous 2008 edition. 1,2 2 | PART -I | Mature B-cell neoplasms | Chronic lymphocytic leukemia/small lymphocytic lymphomaThe presence of large proliferation centers (larger than a microscopic field viewed at 20× magnification), a high mitotic rate (>2.4/hpf) and high Ki-67 expression (>40%) are associated with more aggressive course in patients with CLL/SLL. 3 These neoplasms are more commonly associated with trisomy 12 or del(17p). 4 A more recent paper has linked proliferation centers to a higher frequency of TP53 mutation. 5 Nuclear expression of lymphoid-enhancer-binding factor 1 (LEF1) has been suggested as a highly specific marker for CLL/SLL as it is expressed aberrantly in almost all cases. 6In recent years, our knowledge about the genetic and molecular abnormalities in CLL/SLL has expanded substantially. A classification of CLL/SLL based on "DNA methylation profile" (naïve B cell-like vs memory B cell-like vs intermediate B cell-like) has been introduced showing prognostic value as naïve-like CLLs have mainly unmutated IGH variable (V) genes, whereas most epigenetically intermediate and memory-like CLLs have mutated IGHV. 7 The presence of a specific stereotype of IGH utilized by B-cell receptors may have prognostic significance as shown with the IGHV3-21 gene family. CLL/SLL cases using this family are associated with an adverse outcome regardlessof IGH mutation status. 8,9 There are new insights on the mutational landscape of CLL/SLL cases, especially mutations in SF3B1, TP53, NOTCH1, ATM, and BIRC3 which are associated with lack of response to more conventional therapies and overall poor outcome. 10

A Case Report of Monomorphic Epithelial Intestinal T-Cell Lymphoma and Literature Review

“…The other type of EATL, composed of small to medium-sized tumor cells, was mainly distributed in Asian countries, which accounted for 10% -20% [1]. In the newly revised WHO lymphoma typing of 2016 [2], type II EATL was renamed as MEITL. Some international reports pointed out that affected parts of MEITL are mainly involved in the abdominal cavity and intra-abdominal lymph nodes with gastrointestinal symptoms such as diarrhea as the main manifestation, occasionally found in the skin, ovary, chest and other extraintestinal organs; however there were no reports of combined lung changes as the initial performance.…”

Linfoma folicular no palato duro posterior: Caso clínico

“…Mais raramente poderá haver transformação noutro tipo de linfoma agressivo como: Linfoma de Burkitt, Linfoma de Hodgkin ou Linfoma linfoblástico B. 19 Em suma, os tumores Não -Hodgkin, apesar raros na cavidade oral, devem ser sempre considerados no diagnóstico diferencial quando se suspeita de doenças malignas intra--orais. Pela sua raridade, todos os relatos de caso são importantes para cimentar o conhecimento existente.…”